Open AccessManaging recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin
Author(s) -
Domenica Lorusso,
Antonio González-Martín,
Isabelle RayCoquard
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1123
Subject(s) - trabectedin , medicine , bevacizumab , carboplatin , gemcitabine , oncology , ovarian cancer , paclitaxel , doxorubicin , chemotherapy , pharmacology , surgery , cancer , cisplatin , soft tissue sarcoma , soft tissue
Following the failure of first-line platinum-based chemotherapy in ovarian cancer, options for further therapy in potentially platinum-responsive patients are: carboplatin doublets with pegylated liposomal doxorubicin, gemcitabine or paclitaxel in association with bevacizumab, followed by maintenance with bevacizumab (for nonpretreated patients); or maintenance monotherapy with a poly(ADP-ribose) polymerase inhibitor after a response. The choice of biological therapy depends on a patient’s previous treatments and priority for a symptomatic response. In cases of a rapidly growing tumor or need for symptomatic relief, the addition of bevacizumab should be considered. Patients with limited potential sensitivity to platinum, such as those with a platinum treatment-free interval of 6–12 months, may benefit from intercalation with trabectedin and pegylated liposomal doxorubicin to possibly restore platinum sensitivity.